Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06582745 · ClinicalTrials.gov registry record · Phase 2
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by Cook Children's Health Care System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06582745 is a Phase 2 study of Langerhans Cell Histiocytosis that is actively recruiting participants, run by Cook Children's Health Care System. The registered enrollment target is 75 participants, below the 1,130-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06582745, a Phase 2 study of Langerhans Cell Histiocytosis, is actively recruiting participants, sponsored by Cook Children's Health Care System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric patients.
Conditions Studied
Interventions
- DRUG Trametinib
Study Locations (1)
Texas
- Cook Children's Health Care System - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2039-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06582745
The ClinicalTrials.gov registry entry for NCT06582745 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,130-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (93% lower). The listed sponsor is Cook Children's Health Care System, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 1 intervention - of which Trametinib is the first listed.
NCT06582745 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06582745 about?
NCT06582745 is a clinical study titled "Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib". The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric patients.
What is the current status of trial NCT06582745?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2024-06-24. Estimated completion is 2039-12.
What conditions does trial NCT06582745 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT06582745?
The interventions under investigation include: Trametinib (DRUG).
Who is sponsoring clinical trial NCT06582745?
This trial is sponsored by Cook Children's Health Care System, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06582745 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
COMPLETED · Phase 2
-
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.